Preclinical support for tumor protein D52 as a cancer vaccine antigen

被引:0
|
作者
Bright, Robert K. [1 ,2 ,3 ,4 ]
机构
[1] Texas Tech Univ Hlth Sci Ctr, Dept Immunol & Mol Microbiol, Sch Med, Lubbock, TX 79430 USA
[2] Texas Tech Univ Hlth Sci Ctr, Canc Ctr, Lubbock, TX 79430 USA
[3] Texas Tech Univ Hlth Sci Ctr, Dept Immunol & Mol Microbiol, Sch Med, 3601 4th St, STOP 6591, Lubbock, TX 79430 USA
[4] Texas Tech Univ Hlth Sci Ctr, Canc Ctr, 3601 4th St, STOP 6591, Lubbock, TX 79430 USA
关键词
TPD52 (D52); mD52 (murine orthologue TPD52); hD52 (human orthologue TPD52); overexpressed tumor-self antigen; oncogenic; shared; universal; vaccine; DIFFERENTIAL GENE-EXPRESSION; REACTIVE T-CELLS; PHASE-II TRIAL; BREAST-CANCER; PROSTATE-CANCER; PEPTIDE VACCINATION; COPY NUMBER; TPD52; GENE; TELOMERASE; TARGET;
D O I
10.1080/21645515.2023.2273699
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Overexpressed tumor-associated antigens (TAAs) are a large group that includes proteins found at increased levels in tumors compared to healthy cells. Universal tumor expression can be defined as overexpression in all cancers examined as has been shown for Tumor Protein D52. TPD52 is an over expressed TAA actively involved in transformation, leading to increased proliferation and metastasis. TPD52 overexpression has been demonstrated in many human adult and pediatric malignancies. The murine orthologue of TPD52 (mD52) parallels normal tissue expression patterns and known functions of human TPD52 (hD52). Here in we present our preclinical studies over the past 15 years which have demonstrated that vaccine induced immunity against mD52 is effective against multiple cancers in murine models, without inducing autoimmunity against healthy tissues and cells.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Tumor protein D52: an early tumor marker in ovarian cancer?
    Carol Lovegrove
    Nature Clinical Practice Oncology, 2006, 3 (1): : 8 - 8
  • [2] In vitro models for tumor protein d52 function in cancer cells
    Shehata, M
    Boutros, R
    Bright, RK
    Byrne, J
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S37 - S37
  • [3] In vitro models for tumor protein d52 function in cancer cells
    M Shehata
    R Boutros
    RK Bright
    J Byrne
    Breast Cancer Research, 7
  • [4] The target and the targeted-Tumor protein D52 (TPD52) and cancer
    Chen, Yuyan
    Roslan, Nuruliza
    Frost, Sarah
    Kamili, Alvin
    Cantrill, Laurence
    Byrne, Jennifer A.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S39 - S39
  • [5] Functional Roles of Tumor Protein D52 (TPD52) in Breast Cancer
    Zehtabi, Mojtaba
    Maleknia, Mohsen
    Anbiyaiee, Amir
    Jafari, Razieh Mohammad
    Moramezi, Farideh
    Farzaneh, Maryam
    Azizidoost, Shirin
    CURRENT CANCER THERAPY REVIEWS, 2024,
  • [6] Molecular and Signalling Functions of Tumor Protein D52 in Cancer Cells.
    Shahheydari, H.
    Frost, S.
    Chen, Y.
    Byrne, J.
    MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [7] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer
    Byrne, JA
    Balleine, RL
    Fejzo, MS
    Mercieca, J
    Chiew, YE
    Livnat, Y
    St Heaps, L
    Peters, GB
    Byth, K
    Karlan, BY
    Slamon, DJ
    Harnett, P
    Defazio, A
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (06) : 1049 - 1054
  • [8] Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?
    Byrne, Jennifer A.
    Frost, Sarah
    Chen, Yuyan
    Bright, Robert K.
    TUMOR BIOLOGY, 2014, 35 (08) : 7369 - 7382
  • [9] Tumor Protein D52 as regulator of G protein coupled receptor signaling
    Moepps, B.
    Lutz, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S27 - S27
  • [10] Tumor protein D52 (TPD52) affects cancer cell metabolism by negatively regulating AMPK
    Chen, Yali
    Peng, Changmin
    Tan, Wei
    Yu, Jia
    Zayas, Jacqueline
    Peng, Yihan
    Lou, Zhenkun
    Pei, Huadong
    Wang, Liewei
    CANCER MEDICINE, 2023, 12 (01): : 488 - 499